Osiris Therapeutics
Osiris Therapeutics is a regenerative medicine company that developed RYONCIL, the first FDA-approved mesenchymal stromal cell therapy, for pediatric steroid-refractacute graft-versus-host disease, with commercial rights licensed to Mesoblast Limited.
- Company typePrivate
- Founded1992
- HeadquartersColumbia, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Osiris Therapeutics does
Osiris Therapeutics is a regenerative medicine company founded in 1992 by Kevin Kimberlin and Dr. Arnold Caplan, with operations historically based in Columbia, USA. The company develops therapies based on mesenchymal stem cell (MSC) technology, an adult stem cell platform derived from bone marrow and other tissue sources. Its clinical and commercial work has centered on remestemcel-L, branded RYONCIL, which in 2020 became the first mesenchymal stromal cell therapy to receive FDA approval, indicated for steroid-refractory acute graft-versus-host disease (aGvHD) in pediatric patients.
The company's business model is built around proprietary cell-therapy IP and a partnered commercialization pathway. Rather than commercializing RYONCIL independently, Osiris licensed the asset to Mesoblast Limited for Phase 3 clinical development and global commercialization, receiving milestone and royalty economics in return. This structure allowed Osiris to monetize its MSC platform without standing up proprietary sales, manufacturing scale-up, or distribution infrastructure. The company was publicly traded on NASDAQ under the ticker OSIR and raised capital across multiple funding rounds between 2005 and 2018, including a strategic $15M investment from Mesoblast in 2014.
The entity no longer appears to operate as an independent commercial enterprise. The osiris.com domain is listed for sale, and the company's primary asset sits within Mesoblast's commercial pipeline. Effectively, Osiris has transitioned from an independent MSC development company to an absorbed entity whose principal strategic significance is the provenance of an FDA-approved cell therapy and the associated intellectual property that underpins Mesoblast's commercial positioning. The company reports between 501 and 1,000 employees on its corporate profile, though headcount figures may reflect historic or aggregated disclosures rather than current operational reality.
Osiris Therapeutics firmographics
Firmographics- Name
- Osiris Therapeutics
- Legal name
- Osiris Therapeutics
- Website
- https://osiris.com
- Company type
- Private
- Founded year
- 1992
- Operating status
- Acquired
- Headcount range
- 501–1,000 employees
- Short description
- Osiris Therapeutics is a regenerative medicine company that developed RYONCIL, the first FDA-approved mesenchymal stromal cell therapy, for pediatric steroid-refractacute graft-versus-host disease, with commercial rights licensed to Mesoblast Limited.
- Ownership category
- akta.pro rank
Osiris Therapeutics industry classification
Industry- Product category
- Regenerative Medicine Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
- akta.pro secondary industries
- Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB), Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
Keywords
Where Osiris Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Columbia
- HQ country
- United States
- HQ region
- North America
Markets served
Osiris Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Distribution channels1 record
Osiris Therapeutics product offering
Product offeringCore offering
Osiris Therapeutics develops and patents stem cell-based regenerative medicine products, most notably RYONCIL (remestemcel-L), the first FDA-approved mesenchymal stromal cell (MSC) therapy for treating steroid-refractory acute graft-versus-host disease in pediatric patients two months and older. The company developed this therapy and licensed it to Mesoblast Limited for Phase 3 trials and commercialization, with the product distributed to transplant centers and hospitals across the United States.
Product overview
Osiris Therapeutics is a regenerative medicine company focused on developing cell-based therapies. The company is noted for co-developing RYONCIL, the first FDA-approved mesenchymal stromal cell therapy, which was developed and patented by Osiris Therapeutics and licensed to Mesoblast Limited for Phase 3 trials and commercialization.
Differentiator
Problem solved
Functional benefit
Products and services
- RYONCIL (remestemcel-L) First FDA-approved mesenchymal stromal cell therapy for treating steroid-refractory acute graft-versus-host disease in pediatric patients two months and older; developed and patented by Osiris Therapeutics and licensed to Mesoblast Limited for commercialization, with immediate availability at transplant centers and hospitals across the United States.
Quantifiable outcome
- RYONCIL immediately available at transplant centers and hospitals across the United States
Companies that use Osiris Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Osiris Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Osiris Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Mesoblast LimitedcoreRYONCIL, the first FDA-approved mesenchymal stromal cell therapy developed and patented by Osiris Therapeutics, was licensed to Mesoblast Limited for Phase 3 trials and commercialization. Mesoblast is responsible for bringing the therapy to market across transplant centers and hospitals in the United States.
Recent moves5 records
Expansion highlights2 records
Osiris Therapeutics competitors and assessment
Company assessmentDirect peers
- Mesoblast Limited: Listed parent and commercialization partner for RYONCIL/remestemcel-L. Mesoblast develops MSC-based therapies for inflammatory and immunologic conditions, directly overlapping Osiris's core technology and indication.
- Pluristem Therapeutics: Develops placenta-derived allogeneic cell therapies for hematologic, inflammatory, and ischemic conditions. Competes with Osiris in the allogeneic cell therapy category and has overlapping regenerative medicine positioning.
- Athersys: Clinical-stage cell therapy company developing MultiStem, an off-the-shelf allogeneic stem cell therapy, for ischemic stroke, ARDS, and GVHD—directly overlapping Osiris's MSC-based approach and target indications.
- Vericel Corporation: Commercial-stage cell therapy company with FDA-approved autologous cartilage repair (MACI) and burn wound products. Comparable as a commercial-stage cell therapy developer in regenerative medicine.
- StemCells, Inc. Pioneer in neural and liver stem cell therapies; wound down standalone operations, providing a comparable cautionary precedent for cell therapy developers facing commercialization and capital challenges.
Broad incumbents
- BlueRock Therapeutics: Bayer subsidiary developing iPSC-derived cell therapies for cardiology and neurology. A well-capitalized incumbent in regenerative cell therapy, representing the broader competitive landscape Osiris operates in.
Regional players
- Holostem Terapie Avanzate: European-based developer of advanced stem cell therapies including Holoclar (limbal stem cell therapy). Comparable as a cell therapy company in regenerative medicine, primarily serving European markets.
Emerging players
- BrainStorm Cell Therapeutics: Developer of NurOwn, an autologous MSC-based cell therapy for neurodegenerative diseases (ALS, MS). Uses MSC technology analogous to Osiris's platform but targets neurological indications.
- Capricor Therapeutics: Develops cell therapy products including CAP-1002 (cardiac-derived cell therapy) for Duchenne muscular dystrophy and COVID-19. Comparable as a clinical-stage cell therapy developer in regenerative medicine.
- Cytori Therapeutics: Developed cell therapy technologies using adipose-derived regenerative cells. Comparable as a regenerative medicine company built around adult stem/stromal cell platforms.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Osiris Therapeutics social profiles
Digital presenceOsiris Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Osiris Therapeutics leadership team
Management profileNumber of profiles
Profiles4 records
Osiris Therapeutics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Osiris Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Osiris Therapeutics
What does Osiris Therapeutics do?
Osiris Therapeutics develops and patents stem cell-based regenerative medicine products, most notably RYONCIL (remestemcel-L), the first FDA-approved mesenchymal stromal cell (MSC) therapy for treating steroid-refractory acute graft-versus-host disease in pediatric patients two months and older. The company developed this therapy and licensed it to Mesoblast Limited for Phase 3 trials and commercialization, with the product distributed to transplant centers and hospitals across the United States.
Is Osiris Therapeutics a public or private company?
Osiris Therapeutics is a private company. It is classified as corporate owned and is currently acquired.
When was Osiris Therapeutics founded?
Osiris Therapeutics was founded in 1992. It employs 501 to 1,000 people.
Where is Osiris Therapeutics based?
Osiris Therapeutics is headquartered in Columbia, United States, in the North America region.
Who are Osiris Therapeutics's main competitors?
Direct peers on record are Mesoblast Limited, Pluristem Therapeutics, Athersys, Vericel Corporation and StemCells, Inc.. BlueRock Therapeutics is listed as a broad incumbent. Holostem Terapie Avanzate is listed as a regional player. Emerging players are BrainStorm Cell Therapeutics, Capricor Therapeutics and Cytori Therapeutics.
Does Osiris Therapeutics have an API?
No public API is recorded for Osiris Therapeutics.
What industry is Osiris Therapeutics in?
Osiris Therapeutics's product category is Regenerative Medicine Cell Therapy. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 325414 and its SIC code is 2836.